16
2nd QUARTER 2014
candidates that come out of our research labs
and go into clinical development. It’s unlike
anything I had previously witnessed.”
Keeping It Creative
Landry describes himself as being “very
fortunate to work at one of the most in-
novative companies in the world.” Brilliance
and inventiveness extend into the company
culture. Far from the conventional lab that
comes to mind when one hears “pharma
company,” the Regeneron offices have the
creative energy and work hard/play hard ap-
proach of a Silicon Valley startup (visit bit.ly/
RegeneronVideo for a sense of the company’s
attitude). This style helped to land Regen-
eron at the No. 4 spot on
Forbes
’ Innovative
Companies list last year. Additionally, for two
years in a row the readers of
Science
magazine
have voted Regeneron the best biopharma-
ceutical company in the world to work for.
And, this is the culture
a
nd approach that
Landry wants to help foster as CFO. He has
introduced to his new team several concepts
that he learned at Pfizer
,
like “enabling
functions,” that he believes to be especially
apt for Regeneron.
He was at Pfizer, Inc., for almost four
years, most recently as senior vice president
and treasurer, after two years as senior vice
president of finance for a major division
of the pharmaceutical giant. Prior to that,
Landry served as CFO of Wyeth Australia &
New Zealand before moving into the role of
treasurer for all of Wyeth.
While Landry is now the decision maker
on financial areas of the business, he
emphasizes to his team that in many ways
they provide a “client-services function” for
the executives of other departments in the
organization, from R&D to business
development to legal.
“All these departments have great functional
skills, and I don’t want them wasting their
time on finance matters,” says Landry. “To
the extent that our finance team can come in
and support them on all finance-related
matters, regardless the department, the
better off the company will be. We say ‘use
us.’ They’re our clients.”
Helping him in his transition to his new
role is Murray A. Goldberg, who had served
“ALL THESE
DEPARTMENTS
HAVE GREAT
FUNCTIONAL
SKILLS, AND I
DON’T WANT THEM
WASTING THEIR
TIME ON FINANCE
MATTERS.”
Landry describes Regeneron as a “juggernaut of
research and development,” and sees his role as
ensuring it continues to grow and innovate
FEATURED
CFO
